| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.31 | 6e-16 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.25 | 8e-12 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.26 | 3e-11 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | 0.23 | 2e-10 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.25 | 3e-09 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | 0.19 | 9e-09 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.22 | 1e-08 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.22 | 2e-08 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.19 | 3e-08 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.2 | 4e-08 |